Back

The role of multipoint left ventricular pacing compared to optimized cardiac resynchronization therapy on long-term follow-up in chronic heart failure patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Advanced heart failure Cardiac Resynchronisation Therapy (CRT) ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Polychronis E Dilaveris

National & Kapodistrian University of Athens, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Beneficial SGLT2 inhibitors (SGLT2In) effects in patients with left ventricular assist device (LVAD)
Professor P. Leszek (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Association of left ventricular fibrosis with hemodynamics and myocardial remodeling among patients undergoing left ventricular assist device implant
Doctor G. Gallone (Turin, IT)
Abstract Slides Video
Presentation thumbnail
Comparative study of the effects of left ventricular pacing compared to biventricular pacing on indices of cardiac function and clinical status of heart failure patients READAPT study
Doctor P. Dilaveris (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Improved right ventricular systolic function after cardiac resynchronization therapy in heart failure patients
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video
Presentation thumbnail
Factors associated with successful treatment with temporary right ventricular assist devices for right ventricular failure in recipients of HeartMate 3 left ventricular assist device
Doctor M. Lorente-Ros (Washington, DC, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Session
Late-Breaking Clinical Trials: recent advances in CIED therapies
thumbnail
Congress Session
Late breaking clinical trials: devices
thumbnail
Congress Session
Smaller trials, trial updates, and other studies on heart failure (1)

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources